Telix Pharmaceuticals Limited (ASX:TLX)
Australia
· Delayed Price · Currency is AUD | Market Cap | 9.47B |
| Revenue (ttm) | 783.21M |
| Net Income (ttm) | 49.92M |
| Shares Out | 337.88M |
| EPS (ttm) | 0.14 |
| PE Ratio | 193.91 |
| Forward PE | 66.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,237,289 |
| Average Volume | 1,900,121 |
| Open | 28.76 |
| Previous Close | 29.16 |
| Day's Range | 27.93 - 29.21 |
| 52-Week Range | 14.42 - 31.97 |
| Beta | 2.38 |
| RSI | 54.35 |
| Earnings Date | Apr 17, 2025 |
About Telix Pharmaceuticals
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis o... [Read more]
Financial Performance
In 2024, Telix Pharmaceuticals's revenue was 783.21 million, an increase of 55.85% compared to the previous year's 502.55 million. Earnings were 49.92 million, an increase of 857.95%.
Financial StatementsNews
ATTENTION Telix Pharmaceuticals Limited Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX...
Telix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX)
NEW YORK, NY / ACCESS Newswire / May 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX...
Telix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX)
NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX...
TLX STOCK ALERT: Levi & Korsinsky Notifies Telix Pharmaceuticals Limited Investors of an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / May 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX...
TLX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Telix Pharmaceuticals Limited
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:...
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent
Levi & Korsinsky Announces an Investigation on Behalf of Telix Pharmaceuticals Limited (TLX) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESS Newswire / April 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:...
Telix Pharmaceuticals reports Q1 results; reaffirms FY25 outlook
Telix Reports US$186M Q1 Revenue, Up 62% YOY
Telix Pharmaceuticals reported strong Q1 2025 revenue of $186 million, up 62% year-on-year, driven by Illuccix® sales and RLS Radiopharmacies acquisition.
Citigroup Price Target Trimmed As Analysts Fear Increased Macro Environment-Associated Uncertainty
Citigroup Inc. (NYSE: C) reported on Tuesday that its first-quarter fiscal 2025 revenue growth was 3% year over year and was $21.6 billion, beating the analyst consensus of $21.29 billion. Each of th...
Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients
Telix Pharmaceuticals Limited TLX on Tuesday released preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan1) in recurrent high-grade glioma (brain cancer), substantiating t...
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
MELBOURNE, Australia and INDIANAPOLIS, April 16, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces preliminary results from the Phase 2...
Telix Announces Cardinal Health for Gozellix Commercial Distribution
MELBOURNE, Australia and INDIANAPOLIS, April 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that it has selected Cardinal Health...
Five Below, Telix Pharmaceuticals, Dollar Tree And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Dow Jones index falling over 200 points on Monday. Shares of Five Below, Inc . (NASDAQ: FIVE) rose sharply during Monday's session . JP Morgan analyst Matthew Boss up...
Telix Pharmaceuticals gets new technology chief
Telix Appoints Paul Schaffer as Chief Technology Officer
MELBOURNE, Australia and INDIANAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaf...
Telix Pharmaceuticals: Building A Radiopharma Powerhouse
Anne Whitaker Appointed as Non-Executive Director
MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces the appointment of Anne Whitaker as ...
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
MELBOURNE, Australia, April 02, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX, Telix, the Company) today announces that a first patient has been dosed in the Phase 1 ZO...
ARTMS Drug Master File for Gallium Production Technology Referenced with Telix's Gozellix®
BURNABY, British Columbia, April 01, 2025 (GLOBE NEWSWIRE) -- Telix ARTMS, Inc. (ARTMS), a global leader in radioisotope production technologies, is pleased to announce that the drug master file (DMF)...
Telix Pharmaceuticals Gets FDA Approval for Prostate Cancer Screening Agent
Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for prostate cancer screenings, and shares rose Friday.
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food a...
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health Re...
Telix Adds Lead-212 Isotope Production Capability
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated ...
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
MELBOURNE, Australia and INDIANAPOLIS, March 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the C...